Exogenus Therapeutics is thrilled to announce the granting of a new patent in the United States, marking a major milestone in the company’s global expansion. This is the second region to recognize the patent family titled: “Compositions comprising small extracellular vesicles derived from umbilical cord blood mononuclear cells with anti-inflammatory and immunomodulatory properties and process for obtaining them.” The same patent family has already been granted in Japan.
This innovative technology harnesses Extracellular Vesicles naturally released by umbilical cord blood cells, pre-conditioned in a specific environment, to deliver a novel therapeutic approach for regenerative medicine. Through extensive research, Exogenus has fully characterized these exosomes and their bioactivity, revealing a multifactorial mode of action characterized by an anti-inflammatory and immunomodulatory effect that sets the foundation for next-generation regenerative therapies. Exogenus has also evolved the methods to produce and purify the Extracellular Vesicles with these properties, and which can be utilized for production of Extracellular Vesicles-based products in GMP conditions.
Joana Simões Correia, CEO and inventor of the patent, commented: “Securing this U.S. patent is a significant achievement for Exogenus Therapeutics. It strengthens our intellectual property portfolio, opens doors to a robust international market, and reinforces our commitment to pioneering innovation in regenerative medicine.”
Exogenus Therapeutics’ patent portfolio now includes three families related to its lead product, Exo-101, covering composition, manufacturing processes, and therapeutic applications for inflammatory and fibrotic diseases. Patents have been granted across Canada, China, Japan, Korea, Europe, and the USA.
As a leading exosome biotech company, Exogenus remains dedicated to developing safe, effective, and transformative therapies for patients with unmet medical needs. The company is actively expanding the applications of its proprietary exosomes to address a wide range of conditions involving tissue repair and inflammation control.
Our patents can be accessed here:
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2017163132
Newly granted patent:
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020070700&_cid=P11-LXLUZM-96523-1
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2024105629